Mandi M. Murph
Office: Pharmacy South 334
Voice: (706) 583-0216
Dr. Murph’s laboratory focuses on therapeutic questions of two diseases, melanoma and serous epithelial ovarian carcinoma. For both malignancies, treating patients is coupled with major clinical frustrations, like chemoresistance; this is where science can aid in developing therapeutics and molecular strategies to overcome such obstacles. Enormous progress has been made in the fight against breast and prostate cancer, and childhood leukemia that it is time all cancer subtypes mimic that success. Recently, drugs such as vemurafenib, dabrafenib, trametinib, ipilimumab, pembrolizumab and nivolumab, which treat melanoma, bolster the hope that additional options will soon become available.
Another example of medical therapeutic challenges occurs among women with ovarian cancer. These patients receive debulking surgery followed by adjuvant chemotherapy that reduces their tumors to an undetectable level. Essentially, treatment initially works very well and most patients enjoy a time of remission. However, this is deceiving since 75 to 85 percent of these women will return to the clinic within 18 to 24 months with refractory tumors. The Murph laboratory investigates this question in an attempt to find molecular mechanisms of exploration to either prevent chemoresistance from developing, or prolonging the period of remission by extending the time until chemo resistance develops in slow progressing dormant cells. Chemoresistance will also be a major challenge in melanoma patients. Thus, the development of chemoresistance in mammalian cells is a continuous problem requiring resolution that will ultimately benefit many cancer types.
Chemical inhibitors of cancer, chemoresistance, tumor biology and animal models.